ALT-100 not checked

Aqualung Therapeutics Corp.

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 2 trial completes
Trials
1 active
2 in total
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
How it’s given
“Experimental: Part A : ALT-100 mAB (Dose Escalation) 90 eligible participants will be randomized at a 2:1 ratio to receive a single dose of ALT-100 mAb.”In the company’s words, NCT05938036 on ClinicalTrials.gov
Tested for
Acute Respiratory Distress Syndrome (ARDS)
Main trialPhase 2
“A Phase 2a, multi-center, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of ALT-100mAb in patients with moderate to severe ARDS.”In the company’s words, NCT05938036 on ClinicalTrials.gov

Other drugs for Acute Respiratory Distress Syndrome (ARDS)

All 23 drugs for Acute Respiratory Distress Syndrome (ARDS)

Coming up1

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials2

TrialPhaseCompletesWhat it tests
Phase 2Active, not recruiting 1 May 2027 Study of Safety and Efficacy of ALT-100mAb in Participants With Moderate/Severe ARDS
Phase 1Completed 18 May 2023 First-In-Human Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ALT-100
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow ALT-100

Following is part of Solo: you see every change to ALT-100 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in